Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of SorafenibAndrew X. Zhu, Li‐Tzong Chen, Ronnie T.P. Poon et al.|JAMA|2014Cited by 569
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A. Yu, Pasi A. Jänne, Yasushi Goto et al.|Journal of Clinical Oncology|2023Cited by 224
OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01Helena A. Yu, Pasi A. Jänne, Yasushi Goto et al.|Journal of Thoracic Oncology|2023Cited by 1